COMPANY OVERVIEW
Advancing Pharmaceutical Development Programs
Lobe Sciences Ltd. is a Canadian public biopharmaceutical company focused on advancing high-potential therapeutic assets through disciplined pharmaceutical development. The Company identifies, develops, and de-risks programs addressing unmet medical needs, then partners with established organizations for late-stage development and commercialization.
Our shares trade on the Canadian Securities Exchange (CSE: LOBE), OTCQB (LOBEF), and Frankfurt Stock Exchange (FWB: LOBE).
Through our majority-owned subsidiaries, Cynaptec Pharmaceuticals and Applied Lipid Technologies (ALT), we advance programs within focused entities designed to isolate risk, align capital, and progress assets independently through clinical development.
WHAT WE DO
Our Focus Areas
Rigorous Selection
We identify drug candidates with strong scientific rationale and clear paths to regulatory approval.
Efficient Development
Our capital-efficient model focuses resources on key value-creating milestones.
Strategic Partnerships
We partner with industry leaders to advance late-stage development.
Value Creation
We create value through defined clinical milestones and strategic transactions.
Meet Our Leadership Team
Our experienced team brings decades of pharmaceutical industry expertise.